

Corinne Vandermeulen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3331618/publications.pdf>

Version: 2024-02-01

52
papers

2,088
citations

236612

25
h-index

243296

44
g-index

53
all docs

53
docs citations

53
times ranked

3115
citing authors

#	ARTICLE	IF	CITATIONS
1	Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein-Barr Virus Vaccine in Healthy Young Adults. <i>Journal of Infectious Diseases</i> , 2007, 196, 1749-1753.	1.9	347
2	Sexual maturation in relation to polychlorinated aromatic hydrocarbons: Sharpe and Skakkebaek's hypothesis revisited.. <i>Environmental Health Perspectives</i> , 2002, 110, 771-776.	2.8	204
3	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. <i>Nature</i> , 2021, 590, 320-325.	13.7	148
4	An Adjuvanted, Low-Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross-Reactive Immune Responses in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2008, 198, 642-649.	1.9	111
5	Outbreak of mumps in a vaccinated child population: a question of vaccine failure?. <i>Vaccine</i> , 2004, 22, 2713-2716.	1.7	102
6	Influenza and pertussis vaccination coverage in pregnant women. <i>Vaccine</i> , 2015, 33, 2125-2131.	1.7	100
7	Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 815-825.	2.3	71
8	Attitudes, beliefs, determinants and organisational barriers behind the low seasonal influenza vaccination uptake in healthcare workers – A cross-sectional survey. <i>Vaccine</i> , 2018, 36, 3351-3358.	1.7	66
9	¹⁸ F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. <i>Journal of Nuclear Medicine</i> , 2019, 60, 683-690.	2.8	63
10	Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. <i>Vaccine</i> , 2007, 25, 4940-4948.	1.7	62
11	Vaccination Coverage in 14-Year-Old Adolescents: Documentation, Timeliness, and Sociodemographic Determinants. <i>Pediatrics</i> , 2008, 121, e428-e434.	1.0	58
12	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2017, 8, 740.	1.6	54
13	Vaccination coverage and sociodemographic determinants of measles-mumps-rubella vaccination in three different age groups. <i>European Journal of Pediatrics</i> , 2008, 167, 1161-1168.	1.3	46
14	The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). <i>European Journal of Pediatrics</i> , 2002, 161, 588-593.	1.3	44
15	Long-term persistence of antibodies after one or two doses of MMR-vaccine. <i>Vaccine</i> , 2007, 25, 6672-6676.	1.7	43
16	Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. <i>Vaccine</i> , 1999, 17, 875-886.	1.7	36
17	Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. <i>Cephalalgia</i> , 2019, 39, 100-110.	1.8	32
18	Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2136-2143.	1.4	32

#	ARTICLE	IF	CITATIONS
19	Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. <i>Vaccine</i> , 2005, 23, 1515-1521.	1.7	31
20	Safety and immunogenicity of non-typeable <i>Haemophilus influenzae</i> - <i>Moraxella catarrhalis</i> vaccine. <i>Vaccine</i> , 2019, 37, 3113-3122.	1.7	30
21	Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2009, 98, 1307-1312.	0.7	29
22	Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. <i>Vaccine</i> , 2011, 29, 3842-3849.	1.7	28
23	The resurgence of mumps and pertussis. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 955-959.	1.4	28
24	Evaluation of Cellular Immunity to Mumps in Vaccinated Individuals with or without Circulating Antibodies up to 16 Years after Their Last Vaccination. <i>Journal of Infectious Diseases</i> , 2009, 199, 1457-1460.	1.9	27
25	Mumps outbreaks in highly vaccinated populations: What makes good even better?. <i>Hum Vaccin</i> , 2009, 5, 494-496.	2.4	26
26	Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. <i>Vaccine</i> , 2021, 39, 2800-2809.	1.7	23
27	Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission. <i>European Journal of Pediatrics</i> , 2022, 181, 571-578.	1.3	23
28	Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. <i>Vaccine</i> , 2009, 27, 6918-6925.	1.7	20
29	Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 73, e661-e671.	2.9	20
30	Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 596-608.	1.4	19
31	Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better?. <i>Vaccine</i> , 2018, 36, 2687-2693.	1.7	18
32	Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice. <i>Immunology</i> , 2010, 131, 33-39.	2.0	15
33	Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1520-1526.	2.8	14
34	Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP-1/4-HBs) combination vaccine. <i>Vaccine</i> , 2007, 25, 7549-7558.	1.7	12
35	Occurrence of atypical HUS associated with influenza B. <i>European Journal of Pediatrics</i> , 2017, 176, 449-454.	1.3	12
36	Increased vaccine uptake and less perceived barriers toward vaccination in long-term care facilities that use multi-intervention manual for influenza campaigns. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 673-680.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. <i>Vaccine</i> , 2009, 27, 1964-1969.	1.7	11
38	The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value. <i>Acta Clinica Belgica</i> , 2023, 78, 78-86.	0.5	9
39	The effect of reconstitution of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up. <i>Vaccine</i> , 1999, 17, 2588-2598.	1.7	8
40	CAREGIVERS' WILLINGNESS TO PAY TO REDUCE THE NUMBER OF VACCINE INJECTIONS IN INFANTS. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 61-63.	1.1	8
41	Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium. <i>Vaccine</i> , 2015, 33, 3026-3034.	1.7	7
42	Recruitment barriers for prophylactic vaccine trials: A study in Belgium. <i>Vaccine</i> , 2017, 35, 6598-6603.	1.7	7
43	Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. <i>Vaccine</i> , 2020, 38, 3227-3234.	1.7	7
44	Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients. <i>Vaccines</i> , 2021, 9, 18.	2.1	7
45	Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial. <i>Vaccine: X</i> , 2021, 9, 100124.	0.9	5
46	Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?. <i>Vaccines</i> , 2020, 8, 628.	2.1	4
47	A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study. <i>Vaccine</i> , 2021, 39, 6628-6636.	1.7	4
48	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384.	1.1	2
49	Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1472-1479.	0.8	1
50	Perceived team roles of medical students: a five year cross-sectional study. <i>BMC Medical Education</i> , 2022, 22, 198.	1.0	1
51	Novel instrument to guide nurse-led consultations with parents of three-year-olds in school health services in Flanders: A feasibility study of SPARK36. <i>Journal of Pediatric Nursing</i> , 2021, , .	0.7	1
52	Implementation of Adolescent Vaccination Programmes Through School. <i>Biologicals</i> , 1997, 25, 155-157.	0.5	0